NCT00911495

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: GlycoMimetics Incorporated · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
DRUG	GMI-1070	Intravenous GMI-1070 given as two doses over the course of one day

Timeline

• Start date: 2009-05-01
• Primary completion: 2010-07-01
• Completion: 2010-09-01
• First posted: 2009-06-02
• Last updated: 2020-05-11
• Results posted: 2013-05-03

Locations

3 sites across 1 country: United States